icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

World’s largest vaccine maker, India’s Serum Institute, to begin local production based on Russia’s flagship Sputnik V Covid jab

World’s largest vaccine maker, India’s Serum Institute, to begin local production based on Russia’s flagship Sputnik V Covid jab
India’s Serum Institute (SII) is set to start producing a local version of Russia’s pioneering Sputnik V Covid-19 vaccine. The firm hopes to make over 300 million doses of the drug each year, with operations starting in September.

Moscow’s sovereign wealth fund, the Russian Direct Investment Fund (RDIF), which finances the vaccine, announced the production partnership with the SII on Tuesday. The product will be known simply as "Sputnik" in India, without the original "V" suffix. 

The technology transfer process in order for India to begin producing doses of the formula to fight Covid-19 has already begun. Russia’s Gamaleya Institute has provided the SII with cell and vector samples, and the cultivation process is underway after getting the green light from India’s drug regulator. 

The first batch of vaccines is expected by September. Once the manufacturing process is streamlined, the SII hopes to produce over 300 million doses of Sputnik each year. 

RDIF CEO Kirill Dmitriev hailed the production agreement, describing it as a “strategic partnership” that serves as an example of “joining forces and expertise to save lives both in India and around the world.”

Also on rt.com Russia's flagship Sputnik V Covid-19 vaccine is effective against all known new variants of the killer virus, developer claims

Pointing to Sputnik’s high efficacy and safety profile, Adar Poonawalla, head of the SII, said that it was “critical” that Sputnik be accessible to people across India and the world. 

“Given the uncertainty of the virus, it is important for international institutes and governments to collaborate and further bolster up our fight against the pandemic,” he noted.

The Indian vaccine maker has already produced 500 million doses of Covid vaccine. In addition to developing its own vaccine, the institute currently produces Covishield, based on the AstraZeneca-Oxford drug, and Covovax, created by US biotech company Novavax. 

Sputnik V has received emergency use authorization in nearly 70 countries around the world. However, it is still awaiting approval from the World Health Organization, as well as EU regulators, despite mounting evidence of its safety and efficacy. Studies in several prestigious medical journals, including data analysis recently published last week by Nature, have pointed to strong evidence that the drug is safe and effective. 

Like this story? Share it with a friend!

Dear readers and commenters,

We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.

Sorry for the inconvenience, and looking forward to your future comments,

RT Team.